Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Recent & Breaking News (TSX:MSCL)

Satellos Bioscience Inc. Announces CEO Letter to Shareholders

Newsfile January 24, 2022

Satellos Bioscience to Participate at Biotech Showcase(TM) Virtual 2022

Newsfile January 6, 2022

Satellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophies

Newsfile December 16, 2021

Satellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16th

PR Newswire December 15, 2021

Satellos Bioscience Announces New Board Appointments

Newsfile December 6, 2021

Satellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlights

Newsfile November 29, 2021

Satellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Services

Newsfile October 27, 2021

Satellos Virtually Opens the Market

PR Newswire September 28, 2021

Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration

Newsfile September 17, 2021

Satellos Bioscience (TSXV:MSCL) has evidence for regeneration in severe model of Duchenne

Brieanna McCutcheon  September 13, 2021

Satellos Bioscience Announces Evidence for Regeneration in Severe Model of Duchenne

Newsfile September 13, 2021

Satellos Bioscience Announces Partnership with Jesse's Journey

Newsfile September 7, 2021

Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A

Newsfile August 30, 2021

Satellos Bioscience (TSXV:MSCL) achieves high-quality image of Duchenne drug target

Trevor Abes  August 27, 2021

Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target

Newsfile August 27, 2021